Fanconi Anemia (FA) is a rare autosomic recessive and X-linked disease with 
chromosomal instability after exposure to crosslinking agents as the hallmark. 
Clinical features of FA are somatic malformations, progressive bone marrow 
failure and cancer proneness, however there is wide clinical heterogeneity. The 
symptom most frequently and early associated with morbidity and mortality is 
progressive pancytopenia in the first decade of life although acute myelogenous 
leukemia (AML) or myelodysplastic syndrome (MDS) can appear before aplastic 
anemia. Squamous cell carcinoma (SCC) of the head-neck, intestinal or genital 
tract has a very high incidence in FA and can appear at young age. This paper 
will focus on treatment of bone marrow failure in FA.